📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Indo Us Bio Tech Submits Q3 and Nine-Month Financial Results for FY 2025-26
Indo Us Bio Tech Limited has submitted its integrated financial filing for the quarter and nine-month period ending December 31, 2025. The submission follows the latest SEBI (LODR) Third Amendment Regulations of 2024 and specific circulars from December 2024 and January 2025. While the cover letter confirms the filing, the detailed financial performance metrics are contained within the attached report. This disclosure is a critical regulatory requirement for maintaining transparency with shareholders regarding the company's mid-fiscal year performance.
Key Highlights
Financial results submitted for the quarter ended December 31, 2025.
Financial results submitted for the nine-month period ended December 31, 2025.
Compliance maintained with SEBI Circular SEBI/HO/CFD/CFD-oD2/CIR/P/2024/185.
Adherence to BSE Circular 20250102-4 and NSE Circular NSE/CML/2025/02 dated January 2, 2025.
Full financial reports made available on the company's official website and exchange portals.
💼 Action for Investors
Investors should download the full integrated filing from the BSE or NSE website to analyze specific revenue and profit growth figures. Compare the Q3 results against the previous year's corresponding quarter to gauge the company's current growth momentum.
Indo Us Biotech Approves Q3 FY26 Unaudited Financial Results
Indo Us Biotech Limited's Board of Directors met on January 21, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board also reviewed and approved the limited review reports provided by the company's auditors. The meeting was brief, lasting only 20 minutes, indicating a standard procedural approval of the quarterly figures. Investors should now analyze the detailed financial statements to assess the company's performance trajectory for the fiscal year.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025
The board meeting was conducted on January 21, 2026, from 14:20 PM to 14:40 PM
Limited review reports from the statutory auditors were obtained and approved by the board
The filing was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015
💼 Action for Investors
Investors should review the detailed financial tables once published to evaluate revenue growth and margin stability. Compare the Q3 results with previous quarters to identify any seasonal trends in the biotech and seed business.
Indo Us Biotech Approves Q3 FY26 Unaudited Financial Results
Indo Us Biotech Limited's Board of Directors met on January 21, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board also reviewed and accepted the limited review reports provided by the statutory auditors. The meeting was conducted efficiently, lasting only 20 minutes from 14:20 to 14:40. This announcement confirms the completion of regulatory requirements for the third quarter of the fiscal year.
Key Highlights
Approval of unaudited financial results for the quarter ended December 31, 2025
Limited review reports from auditors were considered and approved by the board
Board meeting concluded within a 20-minute window (14:20 PM to 14:40 PM)
Compliance maintained under Regulation 30 of SEBI Listing Obligations
💼 Action for Investors
Investors should examine the detailed financial statements once released to analyze revenue and margin trends compared to previous quarters.
Indo Us Biotech Receives ED Summons Under PMLA; Disclosure Delayed by Over One Month
Indo Us Biotech Limited has received a summons from the Directorate of Enforcement (ED), Raipur Zonal Office, under the Prevention of Money Laundering Act (PMLA), 2002. The summons, dated November 20, 2025, requires the Principal Officer to appear and produce specific documents for an ongoing investigation. Although received via email on November 27, 2025, the company only disclosed this to the exchanges on December 29, 2025. While the management claims no immediate material impact, the nature of the investigation and the significant delay in reporting are concerning for shareholders.
Key Highlights
Summons issued under Section 50(2) and 50(3) of the Prevention of Money Laundering Act (PMLA), 2002.
The summons (No. PMLA/SUMMON/RPZO/2025/1983) requires appearance of the Principal Officer and production of documents.
Significant disclosure delay: Summons received on Nov 27, 2025, but reported to exchanges only on Dec 29, 2025.
Company attributes the delay to internal review and legal assessment processes.
Management states there is no immediate material impact on financial or operational activities.
💼 Action for Investors
Investors should exercise extreme caution as ED investigations under PMLA are serious and can lead to asset freezes or reputational damage. The delay in disclosure also raises corporate governance concerns that warrant close monitoring.